Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poliovirus vaccine inactivated - Intravacc/Sinovac/WHO

Next Previous
Drug Profile

Poliovirus vaccine inactivated - Intravacc/Sinovac/WHO

Alternative Names: Eupolio™; Inactivated poliovirus vaccine - Intravacc/Sinovac/WHO; msIPV; Poliovirus inactivated vaccine - Intravacc/Sinovac/WHO; Sabin inactivated polio vaccine - Intravacc/Sinovac/WHO; Sabin IPV - Intravacc/Sinovac/WHO; Sabin strain inactivated poliovirus vaccine - Intravacc/Sinovac/WHO; SII inactivated salk polio vaccine; SII inactivated salk polio vaccine (adsorbed); sIPV; sIPV - Intravacc/Sinovac/WHO; Vero Cell - Intravacc/Sinovac/WHO

Latest Information Update: 05 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intravacc; National Institute of Public Health and the Environment; World Health Organization
  • Developer Intravacc; LG Chem; National Institute for Public Health and the Environment; Sinovac Biotech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Poliomyelitis

Most Recent Events

  • 20 Jul 2023 Sinovac Biotech completes a phase III trial in Poliomyelitis (In adolescents, In children, In infants, Prevention, In adults) in China (IM, Injection) (NCT05386810)
  • 22 May 2023 Phase-III clinical trials in Poliomyelitis (In infants, Prevention) in Pakistan and Bangladesh (IM) (NCT05850364)
  • 09 May 2023 Sinovac plans a phase III trial for Poliomyelitis (In infants, Prevention) in Bangladesh (IM), Pakistan (IM) in May 2023 (NCT05850364)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top